This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Changes in tryptophan metabolite levels in the pathogenesis of inflammatory bowel diseases
1 Pirogov Russian National Research Medical University, Moscow, Russia
2 Kazan State Medical University, Kazan, Russia
3 Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia
4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Correspondence should be addressed: Vladimir A. Sorokin
Ostrovityanova, 1, Moscow, 117997, Russia; ur.liam@a_v_nikoros
Funding: the article is based on the results of implementation of Grant Agreement No. 075-15-2022-310 of April 20, 2022, which provides for federal budget subsidies as state support for the establishment and development of world-class scientific centers conducting research and development in priority areas of scientific and technological advancement.
Author contribution: Sorokin VA — data collection and analysis, literature analysis, manuscript preparation; Apollonova SA — physico-chemical and laboratory analyses, data analysis; Abdulkhakov SR — study planning, data analysis; Shakirova GF — data collection and analysis, literature analysis; Odintsova AH — data collection, patient examination and supervision; Abdulkhakov RA — study planning, data interpretation; Rumyantsev SA — study planning, general guidance; Shestopalov AV — study planning, data analysis, manuscript editing.
Compliance with ethical standards: the study was approved by the Ethics Committee of the Pirogov Russian National Research Medical University (Minutes No. 186 of June 26, 2019). All patients signed a voluntary informed consent to participate in the study.
Inflammatory bowel disease (IBD) encompasses chronic, non-infectious inflammatory disorders of the gastrointestinal tract, including Crohn's disease and ulcerative colitis [1]. Such diseases typically have a relapsing course, characterized by alternating periods of exacerbation and remission. Their clinical presentation is driven by chronic immune-mediated inflammation of the intestinal mucosa, which, as the disease progresses, may lead to damage of the intestinal wall, including ulceration and perforation [2].
The global incidence of inflammatory bowel disease (IBD) is increasing, driven by urbanization, changes in dietary patterns, and environmental factors [3]. Despite the substantial advances achieved in IBD research over the past decades, these diseases remain a major clinical challenge due to their rising prevalence, expanding geographic distribution, incompletely understood etiology and pathogenesis, diagnostic difficulties, and limited treatment efficacy [2].
Disruption of the tolerogenic interaction between the gut microbiota and the mucosal immune system plays a major role in the pathogenesis of IBD [4]. This is supported by evidence that maintaining intestinal homeostasis between the immune system and microbiota is critically important, and any unnatural change in the composition of microbial communities can trigger immune dysregulation and inflammation [5]. Pattern recognition receptors (PRRs), particularly toll-like receptors (TLRs) and NOD-like receptors (NLRs), play a key role in this interaction by recognizing microbial components and regulating immune responses [3]. Numerous studies have shown that the intestinal microbiota is continuously regulated by the mucosal immune system through the activation of these receptor pathways, and even minor disturbances in microbial balance may therefore disrupt immune homeostasis and increase susceptibility to IBD. Moreover, polymorphisms in genes encoding TLRs and NLRs are associated with increased susceptibility to inflammatory bowel diseases, underscoring the importance of these receptors in maintaining immune homeostasis [6].
Tryptophan metabolites, including kynurenines and indoles, act as ligands for the AhR receptors and play an important role in establishing and maintaining tolerogenic interactions between the gut microbiota and the intestinal mucosa. AhR receptors are expressed in intestinal epithelial and immune cells; activated by various microbial metabolites, they regulate the differentiation of regulatory T cells (Tregs) and IL-22-producing type 3 innate lymphoid cells (ILC3s), thereby supporting immune homeostasis and intestinal barrier integrity. Notably, AhR signaling not only helps maintain the intestinal barrier by stimulating the production of mucins and antimicrobial peptides, but also plays the key role in prevention of autoimmune disorders by modulating the balance between pro-inflammatory Th17 cells and anti-inflammatory Tregs [7].
However, previous studies of tryptophan metabolites have typically examined fecal and serum samples separately [8]. A comprehensive understanding of tryptophan metabolism requires parallel analysis of both pools, enabling a more complete assessment of its systemic regulation in the holobiont.
This study aimed to characterize the profiles of indolederived tryptophan metabolites in feces and blood serum from patients with inflammatory bowel disease.
METHODS
The study included 29 patients with IBD, aged 20 to 70 years (11 men and 18 women), who were in the acute phase of the disease.
The diagnosis of IBD was established based on clinical presentation, endoscopic findings, and histological examination.
The control group comprised 36 healthy individuals (age 18–65 years, 13 men and 23 women). The patients had to sign an informed consent to participate in the study. The exclusion criteria were concomitant diseases or conditions affecting the intestinal microbiota, including other inflammatory bowel diseases, malabsorption syndrome, malignant neoplasms, gastrointestinal surgery (except appendectomy), functional bowel disorders, celiac disease, allergies, type 1 or type 2 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease, and psychiatric disorders; use of immunosuppressive, cytostatic, antibacterial, or glucocorticosteroid drugs, probiotics or prebiotics, nonsteroidal anti-inflammatory drugs during the three months preceding the study; obesity or underweight; alcohol or substance abuse; chronic diseases of internal organs; infectious or parasitic diseases; diarrhea (more than three bowel movements per day) for at least three consecutive days during the month preceding the study; pregnancy or lactation.
The sample, randomly selected, was not set before the study, since it was =single-center and one-stage.
Tryptophan metabolites in blood samples and fecal extracts were analyzed using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS). Venous blood was collected into serum tubes without anticoagulant, as serum rather than plasma was required for the analysis. The use of serum also excluded potential effects of anticoagulants on the chromatographic profiles of the metabolites. Blood samples were centrifuged within 30 minutes of collection at 2000 × g for 10 minutes at 4 °C. For deproteinization, 300 µL of methanol was added to 100 µL of serum, mixed, and and centrifuged at 14000 × g for 10 minutes at 4 °C. The resulting supernatant was the liquid analyzed.
Fecal samples weighing 50–100 mg were homogenized in methanol at a ratio of 1 : 10 (w/v). The resulting suspension was centrifuged at 14000 × g for 15 minutes at 4 °C. The supernatant was filtered through 0.22-µm membrane filters before to analysis.
Chromatographic analysis was performed using a C18 column (2.1 × 150 mm, 1.8 µm particle size). The mobile phase A was 0.1% (v/v) formic acid in water, and mobile phase B — 0.1% (v/v) formic acid in acetonitrile. Gradient elution was performed by increasing the proportion of mobile phase B from 5% to 95% over 15 minutes at a flow rate of 0.3 mL/min. The column temperature was maintained at 40 °C.
For mass spectrometric analysis, we used electrospray ionization (ESI) in positive-ion mode. The desolvation temperature was set to 500 °C. Target tryptophan metabolites were detected using multiple reaction monitoring (MRM).
The experimental data were analyzed using MedCalc® Statistical Software, version 20 (MedCalc Software Ltd., Ostend, Belgium). The data are presented as the median and interquartile range (Me [Q25–Q75]). Differences were considered statistically significant at p < 0.05. We used the Mann–Whitney U test for between-group comparisons because the sample was small and the distribution of the studied variables was abnormal.
RESULTS
The fecal tryptophan metabolite levels in the treatment group were different from those in the control group (tab. 1).
The most pronounced difference was observed in indole levels, which were 75-fold lower in patients with IBD, indicating a marked impairment of microbial tryptophan metabolism.
At the same time, the concentrations of other indole derivatives changed significantly. The level of indole-3-acetate increased by 159%, indole-3-butyrate by 44-fold (4305%), indole-3-lactate by 234%, and indole-3-acrylate by 14.7fold (1374%). In contrast, the concentration of indole-3carboxaldehyde decreased by 43%.
The analysis of the resulting data revealed sex-specific changes in the fecal tryptophan metabolite profile of patients with IBD (tab. 2).
In men from the treatment group the fecal indole level dropped by 98.9%, whereas the concentrations of indole3-butyrate, indole-3-lactate, and indole-3-acrylate increased 43.5-fold, 3.8-fold, and 59.8-fold, respectively.
In women from the treatment group, the level of indole markedly decreased by 65.6-fold (98.5%). In contrast, the levels of indole-3-acetate, indole-3-butyrate, indole-3-lactate, and indole-3-acrylate increased by 3.5-fold (247%), 44.7-fold (4365%), 4.4-fold (336%), and 10.4-fold (940%), respectively. The concentration of indole-3-carboxaldehyde, however, dropped by 1.9-fold (46%).
Analysis of blood tryptophan metabolite levels revealed significant differences between patients with IBD and the control group (tab. 3).
In the treatment group, the most pronounced change in blood concentration was observed for tryptamine, which decreased by 84.5% (6.5-fold). Serotonin levels decreased by 27%, which was statistically significant. In contrast, 5-HIAA, the principal metabolite of serotonin, showed comparable levels in the two groups.
Among the tryptophan-derived indole metabolites, only the blood concentration of indole-3-butyrate changed significantly, increasing by 31%. No significant changes were observed in the concentrations of indole-3-lactate, indole-3-propionate, or indole-3-carboxaldehyde.
Blood concentrations of indole-3-acetate were comparable between the groups, in contrast to its marked accumulation in the feces of patients with IBD.
Our study showed that the profiles of blood tryptophan metabolites differed between men and women with IBD (tab. 4).
In men with IBD, tryptamine levels decreased by 81% (5.2-fold), while indole-3-butyrate levels increased by 94.5%. A decrease in tryptamine levels was also observed in women with IBD, and it was more pronounced: by 86% (7-fold). In addition, women with IBD exhibited decreased levels of serotonin (by 42%), indole-3-propionate (by 52%), and indole3-carboxaldehyde (by 40%).
DISCUSSION
The study revealed significant disturbances in tryptophan metabolism in patients with IBD.
Modern research highlights the key role of gut microbial metabolites in regulating immune responses and maintaining intestinal barrier integrity [9]. In particular, indole derivatives, such as indole-3-propionate and indole-3-carboxaldehyde, activate the AhR, which is critically important for maintaining immune homeostasis and protecting the intestinal barrier [10, 11].
In our study, patients with IBD exhibited common alterations in tryptophan metabolite profiles, regardless of sex.
A significant decrease in fecal indole levels, a key bacterially derived metabolite, was observed in patients with IBD. This finding reflects disruption of the symbiotic relationship between the host and gut microbiota, specifically a reduction in microbial tryptophanase activity, which is consistent with previous reports of a diminished abundance of tryptophanase-producing bacteria in IBD [1, 12]. At the same time, we observed compensatory activation of alternative tryptophan metabolism pathways, as evidenced by increased concentrations of indole-3-acetate, indole-3-butyrate, and indole-3-lactate. A similar remodeling of the metabolic profile has been reported in other studies [9, 11]. However, we did not register the expected increase in indole-3propionate levels, possibly due to the selective decrease in the abundance of Clostridium sporogenes, a bacterium involved in its synthesis [13, 14].
Indole is the product of bacterial degradation of tryptophan by tryptophanase, an enzyme predominantly expressed by members of the Enterobacteriaceae family, including Escherichia coli and Proteus spp., as well as by Bacteroides spp. [15]. The subnormal indole production we observed in this study is consistent with previous findings indicating a reduction in tryptophanase-producing bacteria in IBD patients [16]. Notably, even among tryptophanase-active strains that are preserved, the regulation of this enzyme may be impaired, as its expression can be suppressed under the oxidative stress conditions characteristic of the intestinal mucosa in IBD [17]. Indole activates the AhR in intestinal epithelial cells, thereby regulating the expression of genes involved in intestinal barrier integrity and immune responses. In addition, indole and its derivatives modulate inflammatory processes by suppressing the production of pro-inflammatory cytokines, including TNFα and IL6, and by stimulating the production of the antiinflammatory cytokine IL10 [18, 19].
In addition to its direct immunomodulatory effects, indole and its derivatives play a key role in bacterial communication within the intestinal microbiota (quorum sensing, QS). As QS signaling molecules, they regulate the balance between commensal and pathogenic bacteria by suppressing the expression of virulence genes in Enterobacteriaceae [11], as well as by modulating the expression of bacterial factors that ensure epithelial barrier integrity [13]. The decrease in indole levels observed in our study — 75-fold — may substantially disrupt these QS-mediated mechanisms, and such a disruption may explain the compensatory increase in other indole metabolites (indole3-acetate, indole-3-lactate), as well as the excessive growth of opportunistic strains that rely on alternative QS systems [14].
Thus, the marked decrease in indole production we observed in this study may reflect both impaired metabolic activity of the intestinal microbiota and weakening of key intestinal protective mechanisms. These findings are consistent with previous studies demonstrating that indole and its derivatives play an important role in maintaining epithelial barrier integrity and immune homeostasis [10, 19].
According to the literature, disruption of the main indole pathway and reduced tryptophanase activity in the intestinal microbiota against the background of dysbiosis may activate alternative tryptophan-metabolism pathways, leading to the production of physiologically significant indole metabolites [20]. In particular, indole-3-acetate can be derived from indole-3-pyruvate through bacterial aminotransferase- and decarboxylase-mediated reactions [21]. In parallel, indole-3pyruvate can be reduced to indole-3-lactate by specific microbial lactate dehydrogenases [12]. Indole-3-butyrate is formed through chain elongation of precursor metabolites, followed by hydrogenation catalyzed by bacterial dehydrogenases [13].
The absence of the expected increase in indole-3-propionate levels may be attributable to several factors: (1) reduced abundance of specific Clostridium sporogenes strains capable of producing indole-3-propionate; (2) competitive inhibition of acrylate reductase by excess indole metabolites; and (3) disruption of the NADPH-dependent reduction of indole-3acrylate to indole-3-propionate by oxidative stress. [14].
The observed sex-dependent differences in tryptamine changes are particularly noteworthy. In the control group, fecal tryptamine concentrations were significantly higher in men than in women. As IBD progressed, tryptamine levels decreased markedly in men but increased significantly in women. The opposite pattern was observed in the systemic circulation: tryptamine levels, which were initially higher in women than in men in the control group, decreased in women with IBD and declined further in men.
This dynamic may reflect adaptive mechanisms in response to intestinal inflammation. According to the literature, men with IBD exhibit a marked decrease in tryptamine concentrations, which correlates with reduced abundance of Clostridium sporogenes, a key bacterial producer of this metabolite [14]. Recent studies suggest that decreased tryptamine levels in IBD may result from the effects of pro-inflammatory cytokines, particularly IL6, which inhibits bacterial tryptophan decarboxylase, a key enzyme involved in tryptamine synthesis [20]. In contrast, women with IBD show increased tryptamine levels, which may be associated with compensatory activation of alternative mechanisms of its biosynthesis. Experimental studies in ovariectomized animals have demonstrated that estrogens promote the growth of Lactobacillus spp., which can decarboxylate tryptophan to produce tryptamine [11]. Notably, despite increased intestinal tryptamine production, serum tryptamine levels are decreased in women with IBD. This finding may be explained by enhanced hepatic catabolism of tryptamine under the influence of pro-inflammatory mediators [12, 20].
Concurrently, we established significantly reduced blood serotonin concentrations in IBD cases. Female patients exhibited the most pronounced alterations in the metabolism of tryptophan indole derivatives; in particular, we observed a significant increase in the levels of indole-3-acetate, an auxin phytohormone that may regulate the intestinal epithelial barrier. This finding aligns with experimental evidence that estrogens enhance bacterial aminotransferase expression, thereby promoting the conversion of tryptophan to indole-3-pyruvate, a precursor of indole-3-acetate [20]. Sex-based analysis revealed that male patients with IBD have decreased blood tryptamine levels and increased indole-3-butyrate concentrations, whereas female patients showed reduced indole-3-propionate and indole-3-carboxaldehyde levels [11, 12].
Thus, alterations in tryptophan metabolites in both feces and blood indicate complex dysregulation of tryptophan metabolism within the holobiont in IBD [22, 23]. These alterations affect both bacterial metabolite production and degradation processes, including detoxification systems in the liver and intestines [4, 12, 20].
These disorders have a bidirectional effect: on the one hand, they alter the metabolic activity of the microbiota; on the other, they disrupt AhR signaling, leading to dysregulation of immune tolerance mechanisms [24].
This imbalance is an important factor in the pathogenesis of dysbiosis, disrupting the mutually tolerant coexistence between the microbiota and the host. In turn, this disruption is one of the key mechanisms underlying the development of intestinal wall inflammation [25].
CONCLUSIONS
The study revealed significant alterations in tryptophan metabolism in patients with IBD, evident in both the intestinal metabolite profile and their blood serum concentrations. The most pronounced change was a significant decrease in fecal indole levels, indicating disruption of the host — microbiota symbiotic relationship and reduced tryptophanase activity of the intestinal microbiome. We established that IBD triggers compensatory activation of alternative tryptophan metabolism pathways, as reflected by increased concentrations of indole3-acetate, indole-3-butyrate, and indole-3-lactate. However, the absence of the expected increase in indole-3-propionate levels suggests metabolic dysregulation associated with dysbiosis. A statistically significant decrease in blood tryptamine levels was observed in both male and female patients with IBD. Fecal tryptamine levels depended on the patient's sex, which may reflect compensatory activation of alternative biosynthetic mechanisms in women. The ranges of significantly altered metabolites were different in men and women. Men exhibited significant changes in blood levels of tryptamine and indole-3-butyrate, as well as in fecal levels of indole, indole-3-lactate, and indole-3-acrylate. In women, significant changes were observed in blood levels of tryptamine, serotonin, indole-3-propionate, and indole-3carboxaldehyde, as well as in fecal levels of indole, indole3-acetate, indole-3-lactate, indole-3-acrylate, and indole-3carboxaldehyde.